Advancing excellence in laboratory medicine for better healthcare worldwide

CSF-Proteins (WG-CSF)


Name Position Country Term Time in Office
J. Gobom  Chair SE 2nd  2021 01 - 2023 12
B. Arslan Member TR    
U. Andreasson Member SE    
R. Bateman Member US    
F. Becker Member FR    
K. Blennow Member SE    
B. Brix Member DE    
V. Delatour Member FR    
A. Jeromin Member US    
M. Korecka Member US    
J. Kuhle Member CH    
S. Lehmann Member FR    
P. Lewczuk Member DE    
M. Lowenthal  Member US    
S. Rütz Member DE    
L.M.  Shaw Member US    
E. Stoops Member BE    
H. Vanderstichele Member BE    
M. Vandijck Member BE    
E. Vanmechelen Member BE    
H. Zetterberg Member SE    



Terms of Reference 

  • To develop a RMP for CSF amyloid β 1-42
  • To develop a RMP for CSF amyloid β 1-40
  • To develop a RMP for CSF total tau
  • To develop CRMs for CSF amyloid β 1-42
  • To develop CRMs for CSF amyloid β 1-40
  • To develop CRMs for CSF total tau
  • To develop a standardization scheme for Neurofilament light chain - NfL


 Current Projects

  • Two RMPs for CSF amyloid β 1-42 have been published and approved by the JCTLM (C12RMP1 and C11RMP9)
  • A method for measurement of CSF amyloid β 1-40 by SRM has been published and validation of a RMP is ongoing
  • Development of a method for measurement of tau by SRM is ongoing
  • Three CRMs for CSF amyloid β 1-42 have been developed (ERM®-DA480/IFCC, ERM®-DA481/IFCC and ERM®-DA482/IFCC)
  • Collection of CSF for development of CRMs for tau is ongoing 
  • Neurofilament light chain - NfL standardization: NfL is a component of the neuronal cytoskeleton, increasingly recognized as promising biomarker in the clinical evaluation of neurological patients. NfL is released from the neurons to the cerebrospinal fluid (CSF) and blood upon damage. Damage of the peripheral nervous system will also result in a release of NfL primarily into the blood. The concentration in blood is approximately 50 times lower than in CSF, due to the proximity of CSF to the neuronal tissue. Lately, highly sensitive assays enabled a reliable quantification of NfL in blood. The sensitivity and automation implemented with this technology enable the prospective and reliable quantification of NfL concentration in clinical blood samples (plasma and serum). In pilot studies, there is high correlation of different methods with each other, but the absolute concentrations differ. The current project is aimed at standardizing this highly promising biomarker across assay platforms and methods for optimised global implementation of the biomarker in clinical laboratory practice.



List of Corresponding Members, nominated by National Societies 

Name Full and Affiliate Member Societies
Kazuhiko Kotani Japan Society of Clinical Chemistry (JSCC)
Adebayo Afonja Association of Clinical Chemists Nigeria (ACCN)
Sarath Kamburapolage Association for Clinical Biochemistry, Sri Lanka
Hüseyin Kayadibi Turkish Biochemical Society (TBS)


 List of Corresponding Members, nominated by Corporate Members

Name Corporate members
Sandra Rutz ROCHE
Harald Althaus SIEMENS



Working Group Chairs'  contact

Assoc. Prof. Johan GOBOM
Clinical Neurochemistry Laboratory
Inst. of Neuroscience and Physiology
Dept. of Psychiatry and Neurochemistry
The Sahlgrenska Academy at University of Gothenburg
Sahlgrenska University Hospital
SE-431 80 Mölndal

Website developed by Insoft